SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-057146
Filing Date
2023-11-01
Accepted
2023-11-01 08:35:08
Documents
13
Period of Report
2023-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-20231031.htm   iXBRL 8-K 62394
2 EX-99.1 atra-ex99_1.htm EX-99.1 304843
  Complete submission text file 0000950170-23-057146.txt   506811

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atra-20231031_lab.xml EX-101.LAB 14028
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atra-20231031_pre.xml EX-101.PRE 10290
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atra-20231031.xsd EX-101.SCH 2469
7 EXTRACTED XBRL INSTANCE DOCUMENT atra-20231031_htm.xml XML 4892
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 231366686
SIC: 2836 Biological Products, (No Diagnostic Substances)